During the first quarter of 2017, Lonza achieved another record quarter in terms of sales and earnings. The healthy overall company performance resulted from particularly strong performance in the Pharma&Biotech segment and continued robust growth in the Specialty Ingredients segment. “Foll ... more
Currently, you are not logged in to my.chemeurope.com. Therefore, you can remember a maximum of 5 contents.